Newly Diagnosed GBM Efficacy
In newly diagnosed GBM,
Optune Gio + TMZ provided an unprecedented long-term survival benefit
Survival with Optune + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years1,2
Overall survival (5-year survival analysis)1-3
Median OS was significantly extended with Optune Gio—by nearly 5 months (P<0.001)1,2
Optune Gio is a standard of care proven to provide the best opportunity
for greater OS at 5 years vs TMZ alone (13% vs 5%)1,4
Optune Gio + TMZ also significantly improved PFS vs TMZ alone1,2
- Median PFS: 6.7 months vs 4.0 months (P<0.001)
More time on Optune Gio predicted increased significant survival benefit5
Median OS by monthly time (hours/day) on Optune Gio*
- Monthly usage was a predictor of survival benefit, independent of other prognostic factors such as KPS, age, or MGMT methylation status5
*Based on the amount of time Optune Gio was turned on and providing therapy over the course of a month. These data reflect the average patient usage of Optune Gio for the first 6 months of treatment (months 1-6).5
†Approximation, based on percentage of usage.
‡vs TMZ alone.
86% of patients received a survival benefit from Optune Gio because they used it more than half the time (average use ≥12 hours/day)5
GBM, glioblastoma; HR, hazard ratio; KPS, Karnofsky Performance Score; MGMT, O-6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide.
References: 1. Optune Gio. Instructions For Use. Novocure; 2023. 2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 3. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 4. Novocure Data on File US-DOF-0035. 5. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473.